Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235343 | 0.88 | HTR2A (0.52) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL1059539 | 0.87 | HTR2A (0.60) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL27126 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL21097121 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL21098059 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL23922815 | 0.84 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL30871778 | 0.83 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL7989561 | 0.83 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL15459741 | 0.83 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL21097658 | 0.82 | BCL9 (0.56) | HTR2AGAABCL9CTNNB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2024259930-A9 | PHOSPHONATE COMPOUND AND MEDICAL USE THEREOF | 润佳（苏州）医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025080879-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024259930-A1 | PHOSPHONATE COMPOUND AND MEDICAL USE THEREOF | 润佳（苏州）医药科技有限公司 | 2024-12-26 | — | — | WO | disclosed |
| CN-118561872-A | Pyrimido-pyridine biological inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2024125642-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2024-02-29 | — | — | US | disclosed |
| US-20240042045-A1 | NANOPARTICLES CONTAINING MULTIPLE CLEAVABLE PRODUGS FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-08 | — | — | US | disclosed |
| CN-117285566-A | Phosphonate compound and medical application thereof | 润佳（苏州）医药科技有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2011101245-A1 | NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPATHIC PAIN | NICOX S.A. (FR) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011092065-A1 | NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPHATIC PAIN | NICOX S.A. (FR) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092065-A1 | NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPHATIC PAIN | NICOX S.A. (FR) | 2011-08-04 | — | — | WO | disclosed |
| WO-2009019534-A2 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | BELLUS HEALTH INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | BELLUS HEALTH INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-6897236-B1 | Aminobenzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS, LTD. (DK) | 2005-05-24 | — | — | US | disclosed |
| EP-1202959-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1-BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| EP-1202959-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1-BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005749-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | HTR2A 1587/4885GAA 299/4885BCL9 3039/4885 |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | HTR2A 4349/4885GAA 1265/4885BCL9 366/4885 |
| US-20240042045-A1 | NANOPARTICLES CONTAINING MULTIPLE CLEAVABLE PRODUGS FOR CANCER THERAPY | LDLR, LRP6, LIPG | HTR2A 3346/4885GAA 137/4885BCL9 1609/4885 |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | DNPEP, DAO, APP | HTR2A 743/4885GAA 206/4885BCL9 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.